Hepatitis B Breakthrough: Functional Cure Achieved

A new experimental drug, bepirovirsen, has demonstrated the potential for a functional cure in chronic hepatitis B patients, a significant advancement in treating the dangerous liver virus. International studies revealed that about 20% of patients receiving the drug achieved a state where their immune system could control the virus, allowing them to stop treatment without relapse.

Developed by GSK and Ionis Pharmaceuticals, bepirovirsen works by binding to the virus's genetic material to suppress replication and a key surface protein. It also stimulates the immune system to help clear the infection. This innovative approach offers a new avenue for a disease that affects over 250 million people globally and causes approximately 1.1 million deaths annually.

In clinical trials, patients receiving bepirovirsen, alongside standard pills, had their virus reduced to undetectable levels. For those who maintained this remission for six months after stopping the bepirovirsen shots, they were also permitted to discontinue their regular medication. While side effects were generally mild, including injection site reactions and temporary enzyme increases, further research is ongoing to understand individual responses and long-term efficacy.